Edesa Biotech, Inc.
EDSADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 14, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
EDSA Earnings Report
EPS Est: $-0.44 | FQ end 2026-06
How EDSA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB01 Cream 0.2% | Phase 2 | Allergic Contact Dermatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Edesa Biotech, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Edesa Biotech, Inc.'s (EDSA) pipeline across Phase 2. Its lead program is EB01 Cream 0.2% (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Edesa Biotech, Inc.'s next FDA catalyst?→
Edesa Biotech, Inc.'s (EDSA) next tracked catalyst is a Earnings expected August 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EDSA biotech catalysts?→
Add EDSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Edesa Biotech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.